Published in Heart Fail Rev on January 01, 2012
Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations. Clin J Am Soc Nephrol (2013) 0.93
Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials. World J Cardiol (2015) 0.75
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol (2007) 6.12
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med (2001) 3.80
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
Hormones and hemodynamics in heart failure. N Engl J Med (1999) 3.50
Nesiritide - not verified. N Engl J Med (2005) 3.41
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 2.35
A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35
Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol (2005) 2.11
Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol (2005) 1.99
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol (2007) 1.94
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res (2003) 1.82
Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail (2006) 1.77
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 1.73
Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun (1988) 1.66
A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail (2008) 1.66
Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol (2005) 1.65
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation (2002) 1.64
Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail (2008) 1.63
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail (2008) 1.57
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol (2003) 1.56
Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure. Congest Heart Fail (2008) 1.49
Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet (1988) 1.48
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail (2009) 1.43
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 1.42
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail (2008) 1.38
Endothelin inhibits renin release from isolated rat glomeruli. Biochem Biophys Res Commun (1988) 1.36
Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation (2006) 1.30
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 1.27
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail (2007) 1.25
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol (2005) 1.23
The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol (2007) 1.15
Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension (2008) 1.13
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.05
Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol (2006) 1.02
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev (2009) 1.02
Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol (2008) 1.01
Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J (1997) 0.99
Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol (2000) 0.99
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol (2007) 0.97
Plasma adenosine levels increase in patients with chronic heart failure. Circulation (1997) 0.96
Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail (2003) 0.93
Endothelin synthesis by rat inner medullary collecting duct cells. J Am Soc Nephrol (1991) 0.92
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001) 0.92
Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail (2008) 0.91
Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest (1989) 0.91
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol (2003) 0.91
Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis. Mol Cell Biochem (2004) 0.89
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail (2004) 0.84
The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J (2001) 0.82
Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol (2003) 0.82
Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol (2007) 0.81
A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest (2001) 0.81
Ultrafiltration does not affect certain predictors of outcome in heart failure. Int J Cardiol (2010) 0.78
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail (2001) 0.78
Ultrafiltration for decompensated heart failure: renal implications. Heart (2009) 0.78
Outcomes of volume-overloaded cardiovascular patients treated with ultrafiltration. J Card Fail (2008) 0.77
Need for a unified decision-making tool for ultrafiltration therapy in heart failure; call for action. Am Heart J (2010) 0.77
Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters. J Card Fail (2006) 0.76
Impact of ultrafiltration on renal function in patients with decompensated heart failure. Congest Heart Fail (2009) 0.75
Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition. Am J Kidney Dis (2005) 1.57
Primary malfunction of a peritoneal dialysis catheter due to encasement in an encapsulating sheath. Perit Dial Int (2007) 1.45
Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant (2005) 1.25
"Bath salts" intoxication. N Engl J Med (2011) 1.22
Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg (2002) 1.09
Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol (2009) 1.07
Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation (2008) 1.06
Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol (2012) 0.97
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol (2011) 0.97
Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney Int (2005) 0.95
Perioperative fluid balance and acute kidney injury. Clin Exp Nephrol (2012) 0.91
Ultrafiltration for acute decompensated heart failure: financial implications. Int J Cardiol (2011) 0.84
Ultrafiltration for heart failure: how fast should we move? Am Heart J (2008) 0.82
Continuous haematocrit monitoring during intradialytic hypotension: precipitous decline in plasma refill rates. Nephrol Dial Transplant (2004) 0.82
The UNLOAD trial: a "nephrologic" standpoint. J Am Coll Cardiol (2007) 0.80
Predictive models for maximum recommended therapeutic dose of antiretroviral drugs. Comput Math Methods Med (2012) 0.79
Shortened hemofilter survival time due to lipid infusion in continuous renal replacement therapy. Nephron Clin Pract (2007) 0.78
In vivo quantification of accumulating abdominal fluid using an electrical impedance tomography hemiarray. Physiol Meas (2010) 0.77
Overcoming financial constraints of ultrafiltration for heart failure. Am J Cardiol (2010) 0.77
Impact of ultrafiltration on renal function in patients with decompensated heart failure. Congest Heart Fail (2009) 0.75
Repurposed biological scaffolds: kidney to pancreas. Organogenesis (2015) 0.75
Ultrafiltration for heart failure: assessment of intravascular volume status through ECG modifications. Ann Noninvasive Electrocardiol (2008) 0.75
Alar photoplethysmography: a new methodology for monitoring fluid removal and carotid circulation during hemodialysis. J Clin Monit Comput (2007) 0.75
Manuscript decision? Please pick a number. Lancet (2005) 0.75